DBV Technologies Free Cash Flow Yield Over Time
| DBVT Stock | USD 4.25 0.28 7.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out DBV Technologies Performance and DBV Technologies Correlation. DBV |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DBV Technologies. If investors know DBV will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DBV Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.30) | Revenue Per Share 0.13 | Quarterly Revenue Growth (0.55) | Return On Assets (0.46) | Return On Equity (1.03) |
The market value of DBV Technologies is measured differently than its book value, which is the value of DBV that is recorded on the company's balance sheet. Investors also form their own opinion of DBV Technologies' value that differs from its market value or its book value, called intrinsic value, which is DBV Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DBV Technologies' market value can be influenced by many factors that don't directly affect DBV Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DBV Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if DBV Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DBV Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Free Cash Flow Yield Analysis
Compare DBV Technologies and related stocks such as POINT Biopharma Global, Oric Pharmaceuticals, and Lyra Therapeutics Free Cash Flow Yield Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORIC | (0.0277) | (0.0277) | (0.0277) | (0.0277) | (0.0277) | (0.0277) | (0.0277) | (0.0277) | (0.043) | (0.0315) | (0.0618) | (0.1084) | (0.3306) | (0.1828) | (0.19) |
| LYRA | (0.0574) | (0.0574) | (0.0574) | (0.0574) | (0.0574) | (0.0574) | (0.0574) | (0.0574) | (0.0574) | (0.0582) | (0.234) | (0.5158) | (0.4587) | (0.2466) | (0.26) |
| INBX | (0.0243) | (0.0243) | (0.0243) | (0.0243) | (0.0243) | (0.0243) | (0.0243) | (0.0338) | (0.0439) | (0.0449) | (0.0592) | (0.0489) | (0.1174) | (0.1105) | (0.12) |
| EPIX | 0.0 | 0.0 | (0.0282) | (0.03) | (0.1076) | (0.2069) | (2.0566) | (0.7103) | (0.431) | (0.1097) | (0.0826) | (0.3581) | (0.1452) | (0.0282) | (0.0296) |
| OPT | (0.0173) | (0.4374) | (0.4972) | (0.4318) | (0.2372) | (0.0436) | (0.0434) | (0.1639) | (0.1552) | (0.0134) | (0.1788) | (0.3475) | (1.0434) | (1.097) | (1.04) |
| MOLN | (0.0341) | (0.0341) | (0.0341) | (0.0341) | (0.0344) | 0.0367 | (0.072) | (0.0739) | (0.1119) | (0.0081) | (0.0591) | (0.167) | 0.5857 | (0.5306) | (0.5) |
| EWTX | (0.0063) | (0.0063) | (0.0063) | (0.0063) | (0.0063) | (0.0063) | (0.0063) | (0.0063) | (0.0063) | (0.0063) | (0.01) | (0.0452) | (0.1214) | (0.1401) | (0.15) |
| ITOS | (0.1351) | (0.1351) | (0.1351) | (0.1351) | (0.1351) | (0.1351) | (0.1351) | (0.1351) | (0.1351) | (0.0358) | (0.0215) | 0.3125 | (0.1615) | (0.2725) | (0.26) |
| CNTA | (0.0038) | (0.0038) | (0.0038) | (0.0038) | (0.0038) | (0.0038) | (0.0038) | (0.0038) | (0.0038) | (0.0038) | (0.0034) | (0.1345) | (0.6966) | (0.2097) | (0.22) |
| NUVL | (0.0106) | (0.0106) | (0.0106) | (0.0106) | (0.0106) | (0.0106) | (0.0106) | (0.0106) | (0.0106) | (0.0106) | (0.0165) | (0.0435) | (0.0439) | (0.0233) | (0.0244) |
| TARS | (0.0135) | (0.0135) | (0.0135) | (0.0135) | (0.0135) | (0.0135) | (0.0135) | (0.0135) | (0.0135) | (0.0096) | (0.0257) | 0.0068 | (0.1372) | (0.2067) | (0.2) |
| GNFT | 0.0068 | (0.357) | (0.1689) | (0.0562) | (0.0199) | (0.02) | (0.0528) | (0.0717) | (0.1091) | (0.0761) | (0.6271) | 0.5147 | (0.3685) | (0.3284) | (0.31) |
| IKNA | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | (0.0104) | 0.0415 | (0.0336) | (0.1375) | (0.7847) | (0.9749) | (0.93) |
| ANEB | (9.0E-4) | (9.0E-4) | (9.0E-4) | (9.0E-4) | (9.0E-4) | (9.0E-4) | (9.0E-4) | (9.0E-4) | (9.0E-4) | (9.0E-4) | (0.0306) | (0.0448) | (0.1643) | (0.1169) | (0.12) |
| CELC | (0.0228) | (0.0228) | (0.0228) | (0.0228) | (0.0228) | (0.0228) | (0.0305) | (0.0367) | (0.0276) | (0.0586) | (0.0769) | (0.1155) | (0.1674) | (0.1563) | (0.16) |
| MNOV | (10.8526) | (0.5287) | (0.422) | (0.2413) | 0.0111 | (0.0758) | (0.0333) | (0.0305) | (0.0272) | (0.0314) | (0.0465) | (0.0723) | (0.1285) | (0.1013) | (0.11) |
| RZLT | (0.0011) | (0.0011) | (0.0565) | (0.1264) | (0.2507) | (0.5078) | (0.294) | (0.5637) | (0.8724) | (0.9037) | (0.1867) | (0.674) | (0.4404) | (0.2586) | (0.27) |
| IPHA | (0.1023) | 0.2453 | (0.14) | (0.0594) | (0.0517) | 0.2827 | (0.0588) | (0.2064) | (0.0777) | (0.0764) | (0.2309) | (0.169) | (0.0774) | (0.1656) | (0.16) |
| HCWB | (0.0356) | (0.0356) | (0.0356) | (0.0356) | (0.0356) | (0.0356) | (0.0356) | (0.0356) | (0.0356) | (0.0356) | (0.0459) | (0.1328) | (0.3012) | (0.6498) | (0.62) |
DBV Technologies and related stocks such as POINT Biopharma Global, Oric Pharmaceuticals, and Lyra Therapeutics Free Cash Flow Yield description
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.My Equities
My Current Equities and Potential Positions
| DBV Technologies | DBVT |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | France |
| Exchange | NASDAQ Exchange |
USD 4.25
Additional Tools for DBV Stock Analysis
When running DBV Technologies' price analysis, check to measure DBV Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DBV Technologies is operating at the current time. Most of DBV Technologies' value examination focuses on studying past and present price action to predict the probability of DBV Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DBV Technologies' price. Additionally, you may evaluate how the addition of DBV Technologies to your portfolios can decrease your overall portfolio volatility.